The Department of Health and Human Services has told employees they can no longer use Claude, a generative AI tool from Anthropic, as President Trump seeks to blacklist the company from the federal ...

After cutting down its pipeline just a few months ago, OSE Immunotherapeutics is at it again, this time reorganizing as Boehringer Ingelheim walks away from the biotech’s metabolic ...

T-cell engager (TCE) specialist Candid Therapeutics has entered a reverse merger agreement with Rallybio that will allow Candid to trade on the Nasdaq while dumping RallyBio’s rare disease maternal ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.

Over a year after first agreeing to a reverse merger with Pulmatrix, protein degradation biotech Cullgen has instead opted to be bought by Gyre Therapeutics in a ...

Shares of uniQure plummeted more than 40% in premarket trading Monday after the company confirmed the FDA has rejected its current data package for AMT-130, a highly anticipated gene therapy for ...

United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial ...

BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets. | BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to ...

By using a mobile app and patient portal called MyQuest, “adult users can prompt the tool to define test names and medical ...

Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin clearance goals among patients with eczema. | Lynk Pharmaceuticals has reported ...

The Swiss drugmaker reported a phase 3 win for fenebrutinib over Sanofi's Aubagio in RMS in November. In that study, Roche linked its drug candidate to a 59% reduction in the annualized relapse rate ...

Aardvark Therapeutics has seen its share price halve in value after the company paused a phase 3 study of its lead metabolic asset over heart-related data.